DXCM vs REGN: which is the better buy in 2026?
On Alexandria's Compass, DexCom Inc. has the edge with a 91/100 score versus 88/100 for REGN. Here is how they stack up, factor by factor.
DexCom Inc.
NASDAQ:DXCM
The insulin-user story is mature. The non-insulin type 2 and prediabetes wave is what the market keeps mispricing.
Full DXCM analysisRegeneron Pharmaceuticals
NASDAQ:REGN
Dupixent's global dominance and a deep late-stage pipeline make REGN a rare large-cap biotech trading below its growth rate.
Full REGN analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is DXCM or REGN the better buy in 2026?
By Compass Score, DexCom Inc. (NASDAQ:DXCM) edges it at 91/100 versus 88/100 for REGN. Both scores update weekly and reflect a contrarian, forward-looking read, not a recommendation.
How does Alexandria compare DXCM and REGN?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.